NCT00622609 - Anti-MAG First Administration to Human | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 1, 2007

Primary Completion Date

April 9, 2009

Study Completion Date

April 9, 2009

Conditions

Cerebrovascular Accident

Interventions

DRUG

GSK249320A

GSK249320A intravenous infusion will be formulated as 100 milligrams/milliliters in 2 milliliters vials (filled to 1 milliliter), in phosphate buffer and delivered by a syringe and programmable pump.

DRUG

Placebo

Sodium chloride intravenous infusion will be given as matching placebo.

Trial Locations (2)

2031

GSK Investigational Site, Randwick, Sydney

21225

GSK Investigational Site, Baltimore